DEVELOPMENT OF METHODS FOR SCREENING PHARMACOLOGIC TREATMENTS OF SUBSTANCE ABUSE

我们已经开始了一项研究计划，以开发一种实验室模型， 可卡因滥用使用非常低剂量的口服可卡因， 可测量的行为影响，但最小的心血管影响。 的 这项研究计划的第一个协议使用了药物歧视 程序，以探索人类行为的敏感性， 可卡因 最初，该方案中的受试者被教导区分 使用药物区分程序从安慰剂中口服50毫克可卡因。 然后受试者暴露于4个剂量的口服可卡因（6.25 mg，12.5 mg， 25 mg和50 mg）和安慰剂，以确定 受试者能检测到的最低可卡因剂量 在整个 这些管理的心血管和自我报告的情绪影响 这些可卡因的剂量是确定的。 该协议目前 日至今 计划进一步研究可卡因和阿片类药物 可卡因和阿片类自我给药研究 古柯茶的药效学和药代动力学作用， 多项选择的行为模式来筛选药物。

We have begun a program of research to develop a laboratory model of cocaine abuse using very low doses of oral cocaine, doses that produce measurable behavioral effects but minimal cardiovascular effects. The first protocol in this research program uses a drug discrimination procedure to explore the limits of human behavioral sensitivity to oral cocaine. Initially, subjects in this protocol are taught to distinguish 50 mg of oral cocaine from placebo using a drug discrimination procedure. Then subjects are exposed to 4 doses of oral cocaine (6.25 mg, 12.5 mg, 25 mg, and 50 mg) and placebo in random order across days to determine the lowest doses of cocaine that subjects can detect. Throughout all of these administrations the cardiovascular and self-reported mood effects of these cocaine doses are determined. The protocol is currently ongoing. Further studies are planned to study cocaine and opioid drug discrimination, cocaine and opioid self-administration studies, the pharmacodynamic and pharmacokinetic effects of coca tea, and a multiple-choice behavioral paradigm for screen medications.